Resistance management of trastuzumab injection (subcutaneous injection) (Herceptin Hylecta)

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) is a drug of choice for the treatment of breast cancer. HER2 overexpression is a factor in poor prognosis of breast cancer, and anti-HER2 treatment can improve the survival rate of these patients. The dual-targeted combination of pertuzumab and trastuzumab and cytotoxic chemotherapy are the main treatment options for patients with early-stage HER2-positive breast cancer. Antibody drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) also improve outcomes for patients with metastatic breast cancer.

There are many reasons for this drug resistance, such as Upregulation of HER2 expression, abnormal activation of HER2 downstream signaling pathways, loss of tumor suppressor genes, cell cycle disorders, and low infiltration of tumor immune cells. Doctors may choose other treatments or use a combination of different drugs instead of trastuzumab based on the patient's specific situation. This helps patients continue to receive effective treatment. Combination therapy can act on tumors simultaneously through different mechanisms and reduce tumor resistance to trastuzumab. Surgery may be an effective option for some patients. Resistance to trastuzumab can be reduced or eliminated by surgical removal of the tumor.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.